Referenser

Leadership

  • [BOT] BOTOX® Summary or Product Characteristics.
  • [BRI14] Brin MF, et al. Biologics. 2014;8:227–241.
  • [DOF012] Allergan. Data on File. VIS/012/FEB2012.
  • [DOF0156] Allergan. Data on File. INT/0156/2015.
  • [DOF0159] Allergan. Data on File. INT/0159/2015.
  • [DOF0179] Allergan. Data on File. INT/0179/2015.
  • [DOF018] Allergan. Data on File. INT/0018/2014.
  • [DOF0423] Allergan. Data on File. INT/0423/2016.
  • [DOF0048] Allergan. Data on File. INT/0048/2015.
  • [DOF0572] Allergan. Data on File. INT/0572/2016.
  • [DOF0681] Allergan. Data on File. INT/0681/2017a.
  • [DOF0663] Allergan. Data on File. INT/0663/2016.
  • [DOF0721] Allergan. Data on File. INT/0721/2017.
  • [DOF0837] Allergan. Data on File. INT/0837/2016.
  • [DYS] Dysport® SmPC.
  • [FER12] Fernandez-Salas E et al. PLoS ONE 2012; 7(11): e49516.
  • [KAR08] Karseuty G, et al. Eur Uro 2008; 53: 275-287.
  • [MAR05] Marchetti A el al. Move Dis 2005; 20: 937-944.
  • [MOH13] Mohindru et al. Poster presented at ICTD, Hannover, Germany 2013; 12-13 May: 1.
  • [SmPC] Botox® Summary of Product Characteristics [2016-02-18].
  • [XEO] Xeomin® UK Summary of Product Characteristics.

Kronisk migrän

  • [AUR11] Aurora SK, et al. Headache 2011 ; 51: 1358–1373.
  • [AUR16] Aurora SK, et al. PF28. Presented at the American Headache Society (AHS) 58th Annual Scientific Meeting, June 9–12, 2016.
  • [BIG0S] Bigal ME, et al. Neurology 2008; 71: 559–566.
  • [BLU10] Blumenfeld AM, et al. Headache 2010; 50: 1406–1418.
  • [BUS10] Buse DC, et al. J Neurol Neurosurg Psychiatry 2010; 81: 428-432.
  • [BUS16] Buse DC, et al. Mayo Clin Proc 2016; 91: 596–611.
  • [BUS16a] Buse DC, et al. 121. ABSTRACT Presented at the American Academy of Neurology (AAN) 2016 Annual Meeting, April 15–21, 2016.
  • [DOD10] Dodick OW, et al. Headache 2010; 50: 921-936.
  • [DOD16] Dodick OW, et al. Headache 2016  doi: 10.1111/head.12774. [Epub ahead of print]
  • [HEP14a] Hepp Z, et al. Cephalalgia 2015; 35: 478–488.
  • [HEP14b] Hepp Z, et al. J Man Care Pharm 2014b; 20: 22–33.
  • [LIP11] Lipton RB. Headache 2011; 51 (82): 77-83.
  • [LIP16] Lipton RB, et al. Cephalalgia 2016: 0333102416652092.
  • [NAT10] Natoli JL, et al. Cephalalgia 2010; 30: 599–609.
  • [OLE13] Olesen J, et al. Cephalalgia 2013; 33(9): 629-808.
  • [SIL15] Silberstein SD, et al. J Neurol Neurosurg Psychiatry 2015; 86: 996–1001.
  • [SmPC14] BOTOX® Summary of Product Characteristics.

Cervikal dystoni

  • [CHA] Charles D, et al. Clin Neuropharmacol 2012; 35(5): 208-214.
  • [DOF0048] Allergan. Data on File. INT/0048/2015.
  • [JAN11] Jankovic J, et al. BMC Neurol 2011; 11(140): 1-7.
  • [JAN15] Jankovic J, et al. J Neurol Sci 2015; 349(1-2): 84-93.
  • [MOL] Molho ES, et al. Mov Disord Clin Pract [Accepted for publication]
  • [MEJ] Mejia NI, et al. Mov Disord 2005: 20(5); 592-597.
  • [SmPC] Botox® Summary of Product Characteristics [2016-02-18].

Spasticitet efter stroke

  • [BRA02] Brashear A, et al. N Engl J Med 2002; 347(6): 395—400.
  • [DIC09] Di Carlo A. Age Ageing 2009; 38: 4—5.
  • [DYS] Dysport® Summary of Product characteristics.
  • [FEI14] Feigin V, et al. Lancet 2014; 383:245–254.
  • [KAJ10] Kaji R, et al. J Neurol 2010; 257: 1330—1337.
  • [LUN10] Lundström E, et al. J Rehabil Med 2010; 42: 296—301.
  • [NSA06] National Stroke Association Stroke Perceptions study 2006.
  • [OEC15] OECD, 2015. Health at a glance 2015: OECD indicators (8: Quality of care). Available at: http://www.oecd.org/health/health-systems/44117530.pdf [Accessed September 2016].
  • [OPH15] Opheim A, et al. Neurology 2015; 85(10): 873—880.
  • [ROS11] Rosales R, et al. Parkinsonism Relat Disord 2011; Suppl 1:S3—10.
  • [SmPC] Botox® Summary of Product Characteristics [2016-02-18].
  • [STI13] Stinear C, et al.Stroke 2013; 44(7):2039—2045.
  • [THI13] Thibaut A, et al. Brain Inj 2013; 27(10): 1093—1105.
  • [URB10] Urban PP, et al. Stroke 2010; 41: 2016—2020.
  • [WEI] Wein T, et al. Poster presented at the European Congress of Physical and Rehabilitation Medicine, 26th-31st May 2014, Marseille, France; Allergan Data on File 029.
  • [WHO12] Wittenauer R and Smith L. World Health Organization Background Paper 6.6 Ischaemic and Haemorrhagic stroke. 2012. Available at: http://www.who.int/medicines/areas/priority_medicines/BP6_6Stroke.pdf [Accessed July 2016].
  • [XEO] Xeomin® Summary of Product Characteristics.
  • [ZOR16] Zorowitz R, et al. Am J Phys Med Rehabil 2016; doi: 10.1097/PHM.0000000000000605.

Idiopatisk överaktiv blåsa

  • [ABR00] Abrams P, et al. Am J Manag Care 2000; 6 (Suppl): S 580–90.
  • [CAS11] Castro D, et al. Act Urol Esp 2011; 35(2): 73–79.
  • [CHA14] Chancellor M, et al. Urol Pract 2014; 1: 7–12.
  • [DSO08] D’Souza AO, et al. J Manag Care Pharm 2008; 14: 291–301.
  • [EVE15] Everaert K, et al. Int J Urol. 2015; 22: 1131-1137.
  • [EAUUI] Lucas MG, et al. EAU Guidelines on urinary incontinence 2015. Available from: http://uroweb.org/guideline/urinary-incontinence/ (last accessed September 2015).
  • [NIT13] Nitti VW, et al. J Urol 2013; 189: 2186–93.
  • [NIT14P] Nitti VW, et al. Poster MP38 presented at Annual Meeting of the American Urological Association, May 16-21, 2014 Orlando, FL, USA.
  • [PIN15] Pindoria N, et al. Poster P60 presented at Annual Meeting of the British Association of Urological Surgeons, June 15-18, 2015 Manchester, UK.
  • [SIN11] Sinclair AJ and Ramsay IN. The Obstetrician and Gynaecologist 2011; 13: 143–148.
  • [SmPC] BOTOX® Summary of Product Characteristics.
  • [TUB04] Tubaro A. Urology 2004; 64: 2–6.
  • [WAG12] Wagg A, et al. BJUI 2012; 110(11): 1767–1774.

Neurogen överaktiv blåsa

  • [CHA14] Chancellor M, et al. Urol Pract 2014; 1: 7–12.
  • [EAUUI] Lucas MG, et al. EAU Guidelines on urinary incontinence 2015. Available from: http://uroweb.org/guideline/urinary-incontinence/ (last accessed September 2015).
  • [KEN13] Kennelly M, et al. Urology 2013; 81: 491–97.
  • [SmPC] BOTOX® Summary of Product Characteristics.

Juvenil cerebral pares

  • [DIC] Dickinson HO, et al. Lancet 2007; 369(9580): 2171-2181.
  • [DOF48] Allergan data on file: 0048.
  • [GEI] Geister TL, et al. Qual Life Res 2014; 23(3): 887-896.
  • [KOM] Koman AL, et al. Pediatrics 2001; 108(5): 1062-1071.
  • [SmPC] BOTOX® Summary of Product Characteristics.

Axilliär hyperhidros

  • [LÄK11] Läkartidningen nr 47 2011 volym 108, sid 2428-2432
  • [NNJ01] Naumann MK and Lowe NJ BMJ, 2001; 323:596-599.
  • [NBJ02] Naumann MK, Hamm H, Lowe NJ Brit J Dermatol, 2002;147:1-9.
  • [SmPC] Botox® Summary of Product Characteristics.